Translating stellar science into breakthrough medicines

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel tumor-targeted and immuno-oncology therapies based on its pioneering research in cancer epigenetics.

Founded in 2008 by seasoned scientific, medical and business leaders, Constellation was the first biopharmaceutical company to target selective regulators of epigenetic function as a potential therapeutic approach.

Research at Constellation and by others has shown that modulating epigenetic regulation has the potential to be a powerful avenue for the development of breakthrough new medicines for cancer and other immune-mediated diseases.

With a decade of experience and an unparalleled understanding of the field, Constellation is using its fully integrated drug discovery and development platform to create a robust pipeline of programs across epigenetic targets to develop small-molecule therapies for difficult-to-treat cancers.